The Association Between Short-Acting β2-Agonist Over-Prescription, and Patient-Reported Acquisition and Use on Asthma Control and Exacerbations: Data from Australia
-
Published:2024-02-04
Issue:3
Volume:41
Page:1262-1283
-
ISSN:0741-238X
-
Container-title:Advances in Therapy
-
language:en
-
Short-container-title:Adv Ther
Author:
Price DavidORCID, Jenkins Christine, Hancock Kerry, Vella Rebecca, Heraud Florian, Le Cheng Porsche, Murray Ruth, Beekman Maarten, Bosnic-Anticevich Sinthia, Botini Fabio, Carter Victoria, Catanzariti Angelina, Doan Joe, Fletton Kirsty, Kichkin Ata, Le Thao, Le Lievre Chantal, Lau Chi Ming, Novic Dominique, Pakos John, Ranasinghe Kanchanamala, Roussos Alexander, Samuel-King Josephine, Sharma Anita, Stewart Deb, Willet Bruce, Bateman Eric, , Campbell Rob, Liu Ying, O’Sullivan Nicole, Rejda Ondrej, Sugg Lisa, James Steph, Dhillon Kiran, Jones Sophie
Funder
Optimum Patient Care Australia AstraZeneca
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Crooks MG, Faruqi S. It is time to end our love affair with short-acting β(2)-agonists in asthma. ERJ Open Res. 2022;8:00353–2022. 2. Martin MJ, Harrison TW. Is it time to move away from short-acting beta-agonists in asthma management? Eur Respir J. 2019;53:1802223. 3. Blakeston S, Harper G, Zabala MJ. Identifying the drivers of patients’ reliance on short-acting β2-agonists in asthma. J Asthma. 2021;58:1094–101. 4. Bloom CI, Cabrera C, Arnetorp S, Coulton K, Nan C, van der Valk RJP, et al. Asthma-related health outcomes associated with short-acting β(2)-agonist inhaler use: an observational UK study as part of the SABINA Global Program. Adv Ther. 2020;37:4190–208. 5. Quint JK, Arnetorp S, Kocks JWH, Kupczyk M, Nuevo J, Plaza V, et al. Short-acting Beta-2-agonist exposure and severe asthma exacerbations: SABINA findings from Europe and North America. J Allergy Clin Immunol Pract. 2022;S2213–2198(22):00285–9.
|
|